| Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ... The Lancet Neurology 19 (4), 307-316, 2020 | 291 | 2020 |
| Orthostatic hypotension and falls in older adults: a systematic review and meta-analysis A Mol, PTSB Hoang, S Sharmin, EM Reijnierse, RJA van Wezel, ... Journal of the American Medical Directors Association, 2018 | 160 | 2018 |
| The emergence of dengue in Bangladesh: epidemiology, challenges and future disease risk S Sharmin, E Viennet, K Glass, D Harley Transactions of The Royal Society of Tropical Medicine and Hygiene 109 (10 …, 2015 | 122 | 2015 |
| Interaction of Mean Temperature and Daily Fluctuation Influences Dengue Incidence in Dhaka, Bangladesh S Sharmin, K Glass, E Viennet, D Harley PLoS Negl Trop Dis 9 (7), e0003901, 2015 | 87 | 2015 |
| Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years T Kalincik, I Diouf, S Sharmin, C Malpas, T Spelman, D Horakova, ... Neurology 96 (5), e783-e797, 2021 | 73 | 2021 |
| Geostatistical mapping of the seasonal spread of under-reported dengue cases in Bangladesh S Sharmin, K Glass, E Viennet, D Harley PLoS neglected tropical diseases 12 (11), e0006947, 2018 | 50 | 2018 |
| Early clinical markers of aggressive multiple sclerosis CB Malpas, AA Manouchehrinia, S Sharmin, I Roos, D Horakova, ... Brain, 2020 | 48 | 2020 |
| Orthostatic hypotension and cognition in older adults: A systematic review and meta-analysis R Iseli, VTV Nguyen, S Sharmin, EM Reijnierse, WK Lim, AB Maier Experimental gerontology, 2019 | 45 | 2019 |
| Profile: the Chakaria Health and Demographic Surveillance System MA Hanifi, A Al Mamun, A Paul, S Al Hasan, S Hoque, S Sharmin, F Urni, ... International journal of epidemiology 41 (3), 667-675, 2012 | 35 | 2012 |
| Updated results of the COVID-19 in MS Global Data Sharing Initiative: anti-CD20 and other risk factors associated with COVID-19 severity S Simpson-Yap, A Pirmani, T Kalincik, E De Brouwer, L Geys, T Parciak, ... Neurology-Neuroimmunology Neuroinflammation 9 (6), 2022 | 34 | 2022 |
| Trajectories of Mini-Mental State Examination Scores over the Lifespan in General Populations: A Systematic Review and Meta-Regression Analysis JM Nagaratnam, S Sharmin, A Diker, WK Lim, AB Maier Clinical Gerontologist, 1-10, 2020 | 27 | 2020 |
| Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis N Lizak, CB Malpas, S Sharmin, EK Havrdova, D Horakova, G Izquierdo, ... JAMA Neurology, 2020 | 27 | 2020 |
| Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study N Seery, S Sharmin, V Li, AL Nguyen, C Meaton, R Atvars, N Taylor, ... CNS drugs, 1-12, 2021 | 25 | 2021 |
| Comparing indigenous mortality across urban, rural and very remote areas: a systematic review and meta-analysis E Carson, S Sharmin, AB Maier, JJ Meij International Health, 2018 | 23 | 2018 |
| The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities, and neuropsychiatric symptoms CB Malpas, S Sharmin, T Kalincik International Journal of Neuroscience, 1-13, 2020 | 18 | 2020 |
| A Bayesian approach for estimating under- reported dengue incidence with a focus on non-linear associations between climate and dengue in Dhaka, Bangladesh S Sharmin, K Glass, E Viennet, D Harley Statistical Methods in Medical Research, 2016 | 18 | 2016 |
| Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis M Le, C Malpas, S Sharmin, D Horáková, E Havrdova, M Trojano, ... Multiple Sclerosis Journal, 1352458520926955, 2020 | 16 | 2020 |
| Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis T Kalincik, S Sharmin, I Roos, MS Freedman, H Atkins, J Burman, ... JAMA Neurology, 0 | 15 | |
| Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis I Roos, S Hughes, G McDonnell, CB Malpas, S Sharmin, C Boz, ... JAMA neurology, 2023 | 11 | 2023 |
| The effectiveness of natalizumab vs fingolimod–a comparison of international registry studies JB Andersen, S Sharmin, M Lefort, N Koch-Henriksen, F Sellebjerg, ... Multiple Sclerosis and Related Disorders, 103012, 2021 | 11 | 2021 |
Tomas KalincikProfessor of Neurology, University of Melbourne and Royal Melbourne HospitalBestätigte E-Mail-Adresse bei unimelb.edu.au
